Spyre Therapeutics

Company snapshot

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Spyre Therapeutics. Not investment advice.

• Peer + 0 momentum

  Lakefront Biotherapeutics NV

  TA overlap score 39.8

• Peer + 0 momentum

  AbbVie

  TA overlap score 28.2

Recent activity

Latest pipeline, patent, and corporate events for Spyre Therapeutics.

1. Jun 8, 2026 Clinical update

   SPY123-201 — Phase 2

2. Jun 5, 2026 Clinical update

   SPYPBO-101 Placebo to SPY072, SPY072 — Phase 2

3. May 23, 2026 Clinical update

   SPY001 — Phase 2

4. May 23, 2026 Clinical update

   SPY002-072 — Phase 2

5. May 23, 2026 Clinical update

   SPY001-001 — Phase 1

View all clinical trial activity →

• What is Spyre Therapeutics?

  Spyre Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker SYRE. Primary therapeutic focus areas include Moderately to Severely Active Rheumatologic Disease, Moderately to Severely Active Ulcerative Colitis, Ulcerative Colitis, Rheum

• Is Spyre Therapeutics publicly traded?

  Yes. Spyre Therapeutics is listed with ticker SYRE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Spyre Therapeutics develop or market?

  We link 1 drug profile(s) where Spyre Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/spyre-therapeutics#company-drugs.

• What are the latest developments for Spyre Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Spyre Therapeutics focus on?

  Spyre Therapeutics focuses on Moderately to Severely Active Rheumatologic Disease, Moderately to Severely Active Ulcerative Colitis, Ulcerative Colitis based on our analysis of their pipeline programs and drug development activities.